Revision history of "A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells" (Q39943622)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 April 2023

  • curprev 19:0919:09, 20 April 2023 KrBot talk contribs 109,978 bytes −1 Set a claim value: title (P1476): A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells undo
  • curprev 19:0919:09, 20 April 2023 KrBot talk contribs 109,979 bytes −1 Changed Dutch label: A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells undo (restore)
  • curprev 19:0919:09, 20 April 2023 KrBot talk contribs 109,980 bytes −1 Changed English label: A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells undo (restore)
  • curprev 19:0919:09, 20 April 2023 KrBot talk contribs 109,981 bytes −1 Changed Asturian label: A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells undo (restore)

12 January 2022

6 August 2021

4 August 2021

14 April 2021

17 July 2020

13 July 2020

9 February 2019

18 January 2019

27 October 2018

20 August 2018

29 June 2018

17 June 2018

2 January 2018

28 September 2017

25 September 2017

23 September 2017

15 September 2017